No Prescription |
 |
 | ||
|
Bactrim |
|
| ||
No Prescription » Prescription Drugs 2 » Bactrim This medication is a combination of two antibiotics used to treat a wide variety of bacterial infections (e.g. middle ear urine respiratory and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type).This medication should not be used in children less than 2 months of age due to the risk of serious side effects.This medication treats only certain types of infections. It will not work for viral infections (e.g. flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness. Buy Bactrim and other Prescription Drugs 2 products online at Medstore. Buy Online at Medstore - Click Here!
About Bactrim: Product Type: Prescription Drugs 2 Bactrim/Bethaprim/Cotrim/Septra DS ( Generic SULFAMETHOXAZOLE / TRIMETHOPRIM ) Bactrim/Bethaprim/Cotrim/Septra DS (Generic SULFAMETHOXAZOLE / TRIMETHOPRIM) Generic SULFAMETHOXAZOLE / TRIMETHOPRIM 960mg 200 Tablets 400(2 x 200 Tablets) 4 x 200 Tablets Generic SULFAMETHOXAZOLE / TRIMETHOPRIM Bactrim/Bethaprim/Cotrim/Septra DS
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
